Subscribe To
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

– The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit – Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years COPENHAGEN, Denmark, Sept. 23, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma […] The post Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency appeared firs...
Read More
Posted: Sep 23 2023, 11:00
Author Name: forextv
Views: 091055